News & events

News & events
<picture><source type="image/webp" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/18e05/Image.webp 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/81bef/Image.webp 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/2d0b8/Image.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/bbd3f/Image.jpg 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/087e6/Image.jpg 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg 2960w" alt=""/></picture>

News
23 June 2022Latest
Immunicum Announces Corporate Rebranding and Name Change to Mendus AB
Learn more
9 June 2022
Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)
Immunicum announced that it has been granted an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST).
Learn more
1 June 2022
Immunicum to Participate in Upcoming Conferences
Immunicum today announced its participation in the following upcoming conferences:...
Learn more
16 May 2022
Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
Immunicum announced today updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead development program DCP-001, a novel therapeutic option for acute myeloid leukemia (AML) maintenance therapy in patients with measurable residual disease (MRD).
Learn more
10 May 2022
Report from the Annual General Meeting of Immunicum AB (publ) on 10 May 2022
At the annual general meeting (the “AGM”) of Immunicum AB (publ), reg. no 556629-1786, (the “Company”), on 10 May 2022 the AGM adopted, inter alia, the following resolutions...
Learn more
10 May 2022
Immunicum AB (publ) Interim Report January – March 2022
Net sales for the period amounted to KSEK 1,794 (–). Result for the period amounted to KSEK -27,582 (-41,571). Earnings and diluted earnings per share totaled SEK -0.14...
Learn more
5 May 2022
Immunicum Appoints Leopold Bertea as Chief Technology Officer
Immunicum today announced the appointment of Leopold Bertea, PhD, as Chief Technology Officer (CTO), effective May 5, 2022.
Learn more

Events
21 September 2022
Upcoming
Sachs 22nd Annual Biotech in Europe ForumThe 22nd Annual Biotech in Europe Forum will take place in-person on September 21-22, 2022, at the Mövenpick Hotel in Basel, Switzerland. Mendus' CEO Erik Manting will present on September 21, 2022.
Learn more
September 2022Upcoming
Pareto Securities’ 13th Annual Healthcare Conference
On 7-8 September 2022, Pareto Securities will host its 13th Annual Healthcare Conference. Mendus' CEO Erik Manting will present at the conference.
Learn more
September 2022Upcoming
LSX Nordic Congress 2022
The LSX Nordic Congress will take place on 6-7 September, 2022, at the AC Hotel Bella Sky in Copenhagen, Denmark. Mendus' CEO Erik Manting will present on June 6, 2022.
Learn more
August 2022Upcoming
Publication of Q2 2022 Results
Mendus will publish the results of the second quarter and first six month of 2022 on August 26th, 2022 at 8am CET.

.FullWidthImage-module--bg-image-mobile--1fPGr.FullWidthImage-module--hide-in-mobile--XC8T7.gbi-1002417752-kyfRk8GRNQvBS5XC5dBx6g:before { opacity: 1; background-image: url('/static/755e562542c233156a7bec1f19e2a86b/afb86/new-events-mobile.png'); }

InvestorsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
Investors

News

Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)

Immunicum to Participate in Upcoming Conferences

Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Report from the Annual General Meeting of Immunicum AB (publ) on 10 May 2022

Immunicum AB (publ) Interim Report January – March 2022

Immunicum Appoints Leopold Bertea as Chief Technology Officer

Events

Sachs 22nd Annual Biotech in Europe Forum

Pareto Securities’ 13th Annual Healthcare Conference

LSX Nordic Congress 2022

Publication of Q2 2022 Results

Investors

Keep up to date